A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
10/2001
10/23/2001	CA2032772C 2-formylbenzylphosphonic acid derivatives, their preparation and their use for the treatment of diseases caused by viruses
10/23/2001	CA2023404C Phosphorylated glycosidase inhibitor prodrugs
10/23/2001	CA1341308C Vaccines against avian herpes viruses
10/23/2001	CA1341307C Nucleotide sequences of avian herpes viruses
10/18/2001	WO2001077687A2 Prion-binding peptidic ligands and methods of using same
10/18/2001	WO2001077371A1 Preincubation assay method
10/18/2001	WO2001077358A2 Herpes viruses for immune modulation
10/18/2001	WO2001077338A2 Human protein kinases and protein kinase-like enzymes
10/18/2001	WO2001077335A2 Listeria monocytogenes genome, polypeptides and uses
10/18/2001	WO2001077297A1 Specific inhibitors of ribosome recycling factor (rrf)
10/18/2001	WO2001077295A1 Mutant bank
10/18/2001	WO2001077294A2 Hpv-specific short-mers
10/18/2001	WO2001077181A2 Anti-rhesus d monoclonal antibodies
10/18/2001	WO2001077174A2 Human transporters and ion channels
10/18/2001	WO2001077158A1 Hepatitis b core antigen fusion proteins
10/18/2001	WO2001077157A2 FULL-LENGTH gb virus c (HEPATITIS G VIRUS) RNA TRANSCRIPTS ARE INFECTIOUS IN PRIMARY CD4 POSITIVE T CELLS AND METHODS OF TREATING HIV
10/18/2001	WO2001077149A2 Regulation of human cyslt2-like gpcr protein
10/18/2001	WO2001077137A1 Albumin fusion proteins
10/18/2001	WO2001077134A2 Process for the preparation of 6-o-propargyl erythromycin derivatives
10/18/2001	WO2001077113A2 Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
10/18/2001	WO2001077103A1 Process for preparing 5'-acetylstavudine
10/18/2001	WO2001077101A1 Chemical compounds
10/18/2001	WO2001077100A2 Benzoamide piperidine compounds as substance p antagonists
10/18/2001	WO2001077091A2 Ns5b hcv polymerase inhibitors
10/18/2001	WO2001077087A1 Novel compounds
10/18/2001	WO2001076638A2 Compositions for drug delivery
10/18/2001	WO2001076637A2 Peptide conjugates for drug delivery
10/18/2001	WO2001076628A1 Chlamydial glycolipid vaccines
10/18/2001	WO2001076627A1 Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies
10/18/2001	WO2001076624A1 Inactivated japanese b encephalitis vaccine and process for producing the same
10/18/2001	WO2001076619A1 Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases
10/18/2001	WO2001076616A1 Tamandarin and didemnin analogs and methods of making and using them
10/18/2001	WO2001076606A2 Use of uric acid or precursors thereof as a treatment for cancer, aids and the like
10/18/2001	WO2001076601A2 Pharmaceutical compositions comprising salmeterol and ipratropium
10/18/2001	WO2001076595A1 Intracorporeal medicaments for high energy phototherapeutic treatment of disease
10/18/2001	WO2001076594A1 Antimicrobial coatings
10/18/2001	WO2001076585A2 Use of thiamphenicol for the treatment of chlamydia pneumoniae infections
10/18/2001	WO2001076572A2 Use of compatible solutes as substances having free radical scavenging properties
10/18/2001	WO2001076570A2 Use of substances that act as cascade inhibitors of the raf/mek/erk signal cascade, for producing a medicament to treat dna and rna viruses
10/18/2001	WO2001076568A2 Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
10/18/2001	WO2001076554A2 Drug delivery composition and device
10/18/2001	WO2001076531A2 Bile acid containing prodrugs with enhanced bioavailability
10/18/2001	WO2001076530A2 Il-8 receptor antagonists
10/18/2001	WO2001039724A3 Phosphonate compounds
10/18/2001	WO2001038548A3 Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors
10/18/2001	WO2001026683A3 Archaeosomes as adjuvants and carriers for acellular vaccines to induce cytotoxic t lymphocyte (ctl) responses
10/18/2001	WO2001025213B1 Pyrrolo imidazole derivatives and their use as medicaments
10/18/2001	WO2001023540A3 P-glycoproteins and uses thereof
10/18/2001	WO2001021201A3 Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen
10/18/2001	WO2001017552A8 Kaposi's sarcoma-associated herpesvirus ks-sm gene product and uses thereof
10/18/2001	WO2000043026A3 Recombinant sp-a for the treatment or prevention of pulmonary infection and inflammation
10/18/2001	WO2000039283A9 Use of cd40 engagement to alter t cell receptor usage
10/18/2001	WO2000037635A3 Genetic suppressor elements against human immunodeficiency virus
10/18/2001	US20010031868 By reaction of a 2,5-diamino-4,6-dihalopyrimidine with formic acid
10/18/2001	US20010031857 Memno peptides, process for their preparation and use thereof
10/18/2001	US20010031779 Methods and materials for treating and preventing inflammation of mucosal tissue
10/18/2001	US20010031777 Heterocyclic compounds and their therapeutic use
10/18/2001	US20010031773 Administering (5-aryl-1,2,4-thiadiazol)-3-yl thiourea and urea derivatives to treat hepatitis, HIV and Kaposi sarcoma, as viricides and anticarcinogenic agents
10/18/2001	US20010031765 Antiviral compounds
10/18/2001	US20010031763 Substituted bis-acridines and related compounds as CCR5 receptor ligands, anti-inflammatory agents and anti-viral agents
10/18/2001	US20010031757 Administering compounds such as 3-(2-phenylethylamino)-6-methyl-1-(2-amino-6-methyl-5-methylene -carboxamidomethylpyridi nyl)-2-pyrazinone, N'-((1-(Aminoiminomethyl)4-piperidinyl) methyl)-N-(3,3- diphenylpropionyl)-L-proline amide
10/18/2001	US20010031749 Antibiotic
10/18/2001	US20010031745 Antiviral purine derivatives
10/18/2001	US20010031740 Mixture containing organic halide
10/18/2001	US20010031728 Fungicides
10/18/2001	US20010031282 Dissolving solid in dimethyl ether under pressure; precipitation; separation
10/18/2001	US20010031267 Method for treatment of canine distemper
10/18/2001	US20010031265 Soaking in solution; then culturing
10/18/2001	US20010031260 Administering tumor necrosis factor antagonist; rheumatic diseases, skin disorders
10/18/2001	US20010031252 Endogenous immune response
10/18/2001	DE10115276A1 Preparation of vaccine against Salmonella, useful for protecting poultry, by inactivating enterotoxins and cytotoxins from the serovar 'Weltevreden'
10/18/2001	DE10014127A1 Antibacterial, fungicidal, antiviral, antiparasitic and herbicidal agents for medicinal, veterinary or agricultural use, comprising amino- or imino-substituted organophosphorus compounds having nitrogen-containing spacer group
10/18/2001	CA2409782A1 Drug delivery composition and device
10/18/2001	CA2406485A1 Hpv-specific short-mers
10/18/2001	CA2406352A1 Peptide conjugates for drug delivery
10/18/2001	CA2406233A1 Compositions for drug delivery
10/18/2001	CA2406033A1 Anti-d monoclonal antibodies
10/18/2001	CA2405912A1 Albumin fusion proteins
10/18/2001	CA2405779A1 Tamandarin and didemnin analogs and methods of making and using them
10/18/2001	CA2405568A1 Prion-binding peptidic ligands and methods of using same
10/18/2001	CA2405554A1 Intracorporeal medicaments comprising halogenated xanthenes for high energy phototherapeutic treatment of disease
10/18/2001	CA2405307A1 Application of substances acting as cascade inhibitors of the raf/mek/erk signaling cascade for the production of a drug against infections by dna and rna viruses
10/18/2001	CA2405151A1 Bile acid containing prodrugs with enhanced bioavailability
10/18/2001	CA2405117A1 Specific inhibitors of ribosome recycling factor (rrf)
10/18/2001	CA2405089A1 Benzoamide piperidine containing compounds and related compounds
10/18/2001	CA2405052A1 Chlamydial glycolipid vaccines
10/18/2001	CA2404988A1 Listeria monocytogenes genome, polypeptides and uses
10/18/2001	CA2404971A1 Human protein kinases and protein kinase-like enzymes
10/18/2001	CA2404229A1 Human transporters and ion channels
10/18/2001	CA2403317A1 Mutant bank
10/18/2001	CA2403012A1 Chemical compounds
10/18/2001	CA2401836A1 Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies
10/18/2001	CA2389691A1 A pre-incubation method for an assay of an inhibitor to an hcv rna-dependent rna polymerase
10/17/2001	EP1146125A1 Poxvirus with targeted infection specificity
10/17/2001	EP1146051A2 Erythromycin A derivatives
10/17/2001	EP1146046A2 Pyropheophorbides and their use in photodynamic therapy
10/17/2001	EP1145644A2 Glycoprotein having inhibitory activity against helicobacter pylori colonization
10/17/2001	EP1145001A2 (in vitro) model for gastrointestinal inflammation
10/17/2001	EP1144998A2 Neisseria genomic sequences and methods of their use
10/17/2001	EP1144675A2 Pharmacokinetic-based drug design tool and method

1 ... 1355 1356 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 ... 1798